| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Goodwill impairment | NaN | 0 | NaN | NaN |
| (gain)/loss on disposal of equipment | NaN | 26 | 103 | 531 |
| Net loss | -35,352 | -35,216 | -26,691 | -75,153 |
| Loss on equity method investment | NaN | 0 | NaN | NaN |
| Depreciation and amortization | 151 | 157 | 160 | 422 |
| Deferred income taxes | NaN | 0 | NaN | NaN |
| Operating lease right-of-use and fixed asset impairment | NaN | 4,136 | NaN | NaN |
| Deconsolidation of kalyra | NaN | 0 | 0 | 0 |
| Noncash consideration portion of zentera in-process research and development | NaN | 0 | NaN | NaN |
| Fixed asset impairment | -1,152 | NaN | 0 | 1,152 |
| Non-cash impact of revenues from licensing and sales of intellectual property | NaN | 0 | 0 | 0 |
| Share-based compensation | 3,197 | 3,122 | 4,828 | 12,772 |
| Non-cash recognized loss on mark-to-market of equity securities | 0 | 152 | 3,470 | -2,383 |
| Accretion of discounts on marketable securities, net | 224 | 431 | 517 | 1,815 |
| Accounts receivable | NaN | -5,000 | NaN | NaN |
| Contracts receivable | 5,000 | NaN | 0 | -5,000 |
| Prepaid expenses and other assets | -973 | 698 | -679 | -3,012 |
| Accounts payable and accrued liabilities | -1,451 | -733 | -1,976 | -14,607 |
| Operating lease right-of-use assets and liabilities, net | -250 | 53 | 127 | 21 |
| Net cash used in operating activities | -32,956 | -30,940 | -26,963 | -67,344 |
| Purchases of marketable securities | 29,952 | 30,238 | 49,534 | 59,716 |
| Proceeds from maturities of marketable securities | 60,000 | 60,000 | 60,000 | 130,000 |
| Proceeds from sale of marketable equity securities | NaN | 2,558 | 17,855 | NaN |
| Proceeds from sale of property and equipment | 0 | 129 | 0 | 569 |
| Purchases of property and equipment | 34 | 0 | 0 | 0 |
| Net cash provided by investing activities | 30,014 | 32,449 | 28,321 | 70,853 |
| Proceeds from issuance of common stock, net | NaN | 5,390 | NaN | NaN |
| Proceeds from issuance of common stock under equity incentive plans | 331 | 0 | 115 | 189 |
| Repurchase of common stock | NaN | 9,976 | NaN | NaN |
| Net-settlement of restricted stock unit vesting | 1,454 | 0 | 0 | 0 |
| Net cash (used in) provided by financing activities | -1,123 | -4,586 | 115 | 189 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -4,065 | -3,077 | 1,473 | 3,698 |
| Cash, cash equivalents and restricted cash at beginning of period | 38,622 | 41,699 | -2,383 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 34,557 | 38,622 | 41,699 | NaN |
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)